Health
International trial tests experimental Alzheimer’s drug on symptom-free individuals
The PrevenTRON study evaluates whether Roche's Trontinemab can prevent dementia in adults with elevated biomarker levels.
The short version
- An international phase III trial called PrevenTRON is enrolling approximately 1,600 symptom-free adults aged 55 to 80 to evaluate if Trontinemab can prevent Alzheimer's dementia.[The Guardian]
- Eligible participants without memory problems who test positive for elevated p-tau217 biomarkers will be randomly assigned to receive either the drug or a placebo over four to six years.[The Guardian]
- Early research found Trontinemab cleared amyloid plaques in 90% of early-stage participants within 28 weeks, but trial leaders emphasize its preventive effectiveness remains unproven.[The Guardian]
Key facts
- The phase III PrevenTRON trial aims to recruit roughly 1,600 participants aged 55 to 80 globally who do not have memory symptoms.[The Guardian]
- Participants will be screened for elevated levels of the p-tau217 biomarker before being randomized to receive Trontinemab or a placebo.[The Guardian]
- Earlier findings indicated Trontinemab removed amyloid plaques in 90% of patients with early-stage Alzheimer's or mild cognitive impairment within 28 weeks.[The Guardian]
- The study is planned to run across four to six years and involve at least 15 UK medical centers by year's end.[The Guardian]
What remains uncertain
- Chief investigator Prof Ramin Nilforooshan cautioned that Trontinemab is an investigational drug and whether it will effectively prevent dementia remains unproven.[The Guardian]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.